Table 2 Number of acute medications by generic and drug class in the 183 days before and after index
Erenumab cohort | Baseline | Follow-up | Â | Â | ||
|---|---|---|---|---|---|---|
N = 3171 | Number | % | Number | % | ORa (95% CI) | P value |
Number of generic drugs used | ||||||
 0 | 872 | 27.5% | 1170 | 36.9% | 0.56 (0.51–0.63) | < 0.0001 |
 1 | 1333 | 42.0% | 1205 | 38.0% | ||
 2 | 610 | 19.2% | 514 | 16.2% | ||
 3+ | 356 | 11.2% | 282 | 8.9% | ||
Number of drug classes used | ||||||
 0 | 872 | 27.5% | 1170 | 36.9% | 0.57 (0.51–0.64) | < 0.0001 |
 1 | 1545 | 48.7% | 1387 | 43.7% | ||
 2 | 560 | 17.7% | 453 | 14.3% | ||
 3+ | 194 | 6.1% | 161 | 5.1% | ||